Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Ribociclib

    Virtual Booth

    Contact Supplier

    Ribociclib

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Ribociclib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,696Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Delhi HC Rebukes Patent Office For Delay In Breast Cancer Drug
    Delhi HC Rebukes Patent Office For Delay In Breast Cancer Drug

    18 Mar 2026

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/novartis-case-delhi-hc-pulls-up-patent-office-over-decade-long-delay-in-breast-cancer-drug-approval/articleshow/129641139.cms

    ECONOMICTIMES
    18 Mar 2026
    Share Share
    Olema Oncology Reveals 2025 Financial Results
    Olema Oncology Reveals 2025 Financial Results

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256109/0/en/Olema-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-and-Operating-Results.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Novartis' Kisqali Keeps 1 in 4 Patients Progression-Free
    Novartis' Kisqali Keeps 1 in 4 Patients Progression-Free

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202238/0/en/1-in-4-metastatic-breast-cancer-patients-treated-with-Novartis-Kisqali-remain-progression-free-beyond-4-years.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    BBOT Unveils Posters At San Antonio Breast Cancer Symposium
    BBOT Unveils Posters At San Antonio Breast Cancer Symposium

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3178024/0/en/BBOT-Announces-Poster-Presentations-at-the-San-Antonio-Breast-Cancer-Symposium-SABCS.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177971/0/en/Olema-Oncology-to-Present-Trial-in-Progress-Poster-for-Phase-3-OPERA-02-Trial-of-Palazestrant-Plus-Ribociclib-at-SABCS-2025.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Olema Oncology Unveils Phase 1B/2 Palazestrant + Ribociclib Data
    Olema Oncology Unveils Phase 1B/2 Palazestrant + Ribociclib Data

    18 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/18/3168941/0/en/Olema-Oncology-Announces-New-Data-from-the-Phase-1b-2-Trial-of-Palazestrant-Plus-Ribociclib-in-ER-HER2-Metastatic-Breast-Cancer-at-ESMO-2025.html

    GLOBENEWSWIRE
    18 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.